

Rec'd PCT/PTO 11 AUG 2005

Docket No.: PI4862

## DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE COMPOUNDS AS TACHYKININ  
AND/OR SEROTONIN REUPTAKE INHIBITORS"

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 2 July 2003 as Serial No. PCT/EP2003/007126  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

## Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
0215392.2	GB	3 July 2002	YES

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

Direct all correspondence to the address associated with Customer Number 23347.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Giuseppe ALVARO

Inventor's Signature: Giuseppe Alvaro

Date: 16/05/05

Residence: Verona Italy 1TX

Citizenship: Italian

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: Francesca CARDULLO

Inventor's Signature: Francesca Cardullo

Date: 18/05/05

Residence: Verona Italy 1TX

Citizenship: Italian

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: Lucilla D'ADAMO

Inventor's Signature: Lucilla D'Adamo

Date: 25/05/05

Residence: Verona Italy 1TX

Citizenship: Italian

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: Elisabetta PIGA

Inventor's Signature: Elisabetta Piga

40 Date: 24/05/2005

Residence: Verona Italy

ITX

Citizenship: Italian

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Full Name of Inventor: Catia SERI

Inventor's Signature: Catia Seri

50 Date: 25/05/2005

Residence: Verona Italy

ITX

Citizenship: Italian

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P O Box 13398  
Research Triangle Park  
North Carolina 27709

Rec'd PCT/PTO 11 AUG 2005

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY  
and  
CORRESPONDENCE ADDRESS  
INDICATION FORM**

Application Number	To be assigned
Filing Date	10/521159
First Named Inventor	Giuseppe ALVARO
Title	"N-Benzyl-3-Phenyl-3-Heterocycl-Propionamide Compounds As Tachykinin and/or Serotonin Reuptake Inhibitors"
Art Unit	
Examiner Name	
Attorney Docket Number	PI4862USw

I hereby appoint:



Practitioners associated  
with the Customer  
Number:

23347

OR



Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:



The address associated with the above-mentioned Customer Number:

OR



The address associated with Customer Number:

23347

OR

<input type="checkbox"/>	Firm or Individual Name			
	Address			
	City		State	
	Country			
	Telephone		Fax	

I am the:



Applicant/Inventor.



Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record	
Signature	Date
Name	Telephone
Title and Company	

Charles E. DADSWELL

919-483-6983

Attorney, GLAXO GROUP LIMITED

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.



\*Total of \_\_\_\_\_ forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PI4862USw

## CERTIFICATE UNDER 37 C.F.R. §3.73(b)

Rec'd PCT/PTO 11 AUG 2005

10/521159

Applicant: ALVARO, Giuseppe; CARDULLO, Francesca; D'ADAMO, Lucilla; PIGA, Elisabetta; SERI, Catia  
Application No.: PCT/EP2003/007126 Filed: July 2, 2003  
For: N-Benzyl-3-Phenyl-3-Heterocyclyl-Propionamide Compounds As Tachykinin and/or Serotonin Reuptake Inhibitors

Glaxo Group Limited.

(Name of Assignee)

university, etc.)

Corporation

(Type of Assignee, e.g. corporation, partnership,

certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application identified above. The assignment was recorded on \_\_\_\_\_ in the Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, and for which a copy thereof is attached.

B. ☐ A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or which a copy thereof is attached.

2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or which a copy thereof is attached.


☐ Additional documents in the chain of title are listed here:

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is given below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 07/30/2005  
SmithKline Beecham Corporation  
D/b/a GlaxoSmithKline,  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Telephone No.: (919) 483-2370  
Facsimile No.: (919) 483-7988

Signature:   
By: Charles E. Dadswell  
Title: Patent Attorney (resolution attached)